HOW OUR TECHNOLOGY TARGETS TUMORS
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development and commercialization of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect™ (Phage Display Library), TavoPrecise™ (Tissue-specific biologics engineering platform), and TavoELITE™ (Intracellular Undruggable Target platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates focused on cancers, autoimmune conditions, and infectious diseases in various stages of development. We are globally connected with operations in Asia and North America. Our development strategy includes organic growth, biopharma collaboration, and potential clinical stage asset licensing.
(LOWER GWYNEDD, Pennsylvania, October 28, 2022) Tavotek Biotherapeutics announced today that it has received clearance of its Investigational New Drug....Read More
TavoSELECT™ Phage Library
TavoSELECT™ provides access to antibodies or biomolecules that target membrane proteins, intracellular proteins, or antigens that are more difficult to target due to the blood-brain barrier, etc.
TavoELITE™, a novel platform that goes after intracellular targets for the treatment of cancer and other diseases., a novel platform that goes after intracellular targets for the treatment of cancer and other diseases.
727 Norristown Road, 3 Spring House Innovation Park Suite 101, Lower Gwynedd, Pennsylvania 19002
China. Suzhou. Suzhou Industrial Park. Unit 405, Building C2, No. 218, Xinghu Street
© 2022 Tavotek Biotherapeutics All rights reserved. (267) 405-9426
© 2022 Tavotek Biotherapeutics All rights reserved.(267) 405-9426